Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
At the end of 2022, Sosei Heptares had announced that its long-term collaboration with Pfizer had advanced the first candidate drug, Lotiglipron (PF-07081532), to Phase 2 clinical trials
and has received speaker fees from Sanofi
Any references to metabolic, endocrine, or appetite-related pathways are provided strictly for scientific context within laboratory research and do not imply therapeutic, diagnostic, or clinical use
)
Administration methods vary by intended application, with subcutaneous injection and oral capsule discussions appearing most frequently in peptide protocols
US$ 23.19
US$ 23.06
US$ 21.75
